EFTR
NASDAQeFFECTOR Therapeutics Inc.
Price$0.19+0.00 (+0.00%)
2025-06-042025-07-01
Latest news
25 items- SECSEC Form EFFECT filed by eFFECTOR Therapeutics Inc.EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form EFFECT filed by eFFECTOR Therapeutics Inc.EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form EFFECT filed by eFFECTOR Therapeutics Inc.EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form EFFECT filed by eFFECTOR Therapeutics Inc.EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form 15-12G filed by eFFECTOR Therapeutics Inc.15-12G - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.S-8 POS - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.S-8 POS - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form POS AM filed by eFFECTOR Therapeutics Inc.POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form POS AM filed by eFFECTOR Therapeutics Inc.POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form POS AM filed by eFFECTOR Therapeutics Inc.POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form POS AM filed by eFFECTOR Therapeutics Inc.POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form 25-NSE filed by eFFECTOR Therapeutics Inc.25-NSE - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
- NEWSeFFECTOR Therapeutics Declared in Default on $75M Oxford Finance LoanOn June 25, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received written notice from Oxford Finance LLC (“Oxford”) that events of default have occurred with respect to that certain Loan and Security Agreement dated as of March 19, 2021, as amended (the “Loan and Security Agreement”), by and between Oxford, as collateral agent, the parties who are lenders thereunder, the Company and eFFECTOR Therapeutics Operations, Inc., the Company’s wholly owned subsidiary (the “Oxford Notice”). The Oxford Notice indicates that events of default have occurred under the Loan and Security Agreement’s Section 8.3 (Material Adverse Change) and Section 8.5 (Insolvency). The Oxford Notice indicates that a
- SECSEC Form 8-K filed by eFFECTOR Therapeutics Inc.8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- SECSEC Form 8-K filed by eFFECTOR Therapeutics Inc.8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- NEWSDow Jumps 300 Points; Alimera Sciences Shares Spike HigherU.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.80% to 39,463.48 while the NASDAQ fell 0.42% to 17,614.80. The S&P 500 also rose, gaining, 0.20% to 5,475.44. Leading and Lagging SectorsEnergy shares jumped by 2.6% on Monday. In trading on Monday, information technology shares fell by 1.1%. Top Headline The Federal Reserve Bank of Dallas’ general business activity index for manufacturing in Texas improved to -15.1 in June compared to -19.4 in May. Equities Trading UP Agrify Corporation (NASDAQ:AGFY) shares shot up 107% to $0.5229. Shares of MicroAlgo Inc. (NASD
- NEWSWhy eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%EFFECTOR Therapeutics Inc (NASDAQ:EFTR) shares are trading lower by 75% to $0.28 during Monday’s session after the company announced that it has terminated its employees and will wind down its operations. Also, the company announced it plans to voluntarily request a delisting of its securities on the Nasdaq. This decision follows a special board meeting and the company expects delisting soon. Craig R. Jalbert, who the company says is experienced in managing distressed businesses, has been appointed as the new CEO, President, Treasurer, Secretary and sole board member to oversee the wind-down process. See Also: Gold Prices Set To Climb To $3,000 On Fed Rate Cuts, Geopolitical Tensions,
- NEWSEFFECTOR Therapeutics shares are trading lower after the company announced that it has terminated its employees and will wind down its operations. Also, the company announced it plans to voluntarily request a delisting of its securities on the Nasdaq.
- SECSEC Form 8-K filed by eFFECTOR Therapeutics Inc.8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- NEWSeFFECTOR Therapeutics To Wind Down Operations And Seek Potential Strategic Alternatives, Expects To Delist From Nasdaq
- PReFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from NasdaqSOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d
- SECeFFECTOR Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
- INSIDERSEC Form 4 filed by Director Loewy Caroline M4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
- INSIDERSEC Form 4 filed by Director Klencke Barbara4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
- INSIDERSEC Form 4 filed by Director Ehrlich Christopher B4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
EFTR FAQ
7 questionsWhat does eFFECTOR Therapeutics Inc. do?
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a...Where does EFTR stock trade?
eFFECTOR Therapeutics Inc. (EFTR) is listed on NASDAQ.What sector and industry is EFTR in?
eFFECTOR Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did eFFECTOR Therapeutics Inc. go public?
eFFECTOR Therapeutics Inc. (EFTR) completed its IPO in 2021.What are analysts saying about EFTR?
eFFECTOR Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Credit Suisse: Outperform with a $1600.00 price target on 2022-01-25.What companies are similar to EFTR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EFTR side-by-side with any of them on Quantisnow.How can I track EFTR on Quantisnow?
Quantisnow aggregates eFFECTOR Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EFTR to receive live email and push alerts on every new disclosure.